Phase II data presented for sevuparin in SCD patients with acute painful vaso-occlusive crisis Jan. 7, 2020
Gamida Cell closes in on phase III readout for blood cancer therapy Jan. 2, 2020 By Michael Fitzhugh Nearly four years after its start, a phase III trial of Gamida Cell Ltd.'s ex vivo expanded cord blood candidate, omidubicel, for hematologic malignancies is fully enrolled, the company said. Read More
RSS